Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.
Bon G, Loria R, Amoreo CA, Verdina A, Sperduti I, Mastrofrancesco A, Soddu S, Diodoro MG, Mottolese M, Todaro M, Stassi G, Milella M, De Maria R, Falcioni R.
Bon G, et al. Among authors: mastrofrancesco a.
Oncotarget. 2016 Aug 19;8(65):108463-108479. doi: 10.18632/oncotarget.11400. eCollection 2017 Dec 12.
Oncotarget. 2016.
PMID: 29312543
Free PMC article.